Remap Consulting GmbH
Remap Consulting provides an integrated approach to pharmaceutical pricing & market access solutions.
We are a specialist pricing, reimbursement and market access consultancy offering an integrated, evidence-based approach to optimising market access. Our strength lies in our ability to understand the market access challenges from your perspective and to develop payer-focused solutions tailored to your business needs.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Havas Life London
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…
Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs
MDNT
MDNT is a native Digital and Omnichannel agency focused solely on the healthcare, pharma, and life science industries. We’re highly experienced, no nonesense, and very good at what we do.
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national and international reach. As we understand the healthcare market and…
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…
Company Details
Latest Content from PMHub
UX: Pushing the right buttons
White Papers and Resources | March 31, 2014 | Havas Lynx
Unlocking better outcomes in healthcare with UX
07 Good Pharma
White Papers and Resources | January 3, 2014 | Havas Lynx
Better for patients, better for business
06 Our Opportunity to Rethink the Health Experience
White Papers and Resources | January 3, 2014 | Havas Lynx
Our point of view
05 Social Media: A Health Hazard?
White Papers and Resources | January 3, 2014 | Havas Lynx
The case to embrace going social
Creating a Lifeline to the New Digital User
White Papers and Resources | January 3, 2014 | Havas Lynx
Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about...
Warehousing of HCV patients reaches new high
White Papers and Resources | December 19, 2013 | Inizio
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...
Brand leaders in RA will lose market share, predict rheumatologists
White Papers and Resources | December 19, 2013 | Inizio
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
Removing the Roadblocks to Effective Patient Treatment
White Papers and Resources | November 22, 2013 | Inizio
How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis
White Papers and Resources | November 22, 2013 | Inizio
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...
The Difficulties of Living with Depression Don’t End with the Illness Itself
White Papers and Resources | November 22, 2013 | Inizio
This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.